Bristol-Myers Will Divest Celgene Blockbuster to Close Deal




 

(Bloomberg) -- Bristol-Myers Squibb Co. agreed to divest one of Celgene Corp.'s most lucrative drugs in order to close their planned $74 billion merger.

Under an agreement with the Federal Trade Commission, Bristol-Myers will sell off the psoriasis pill Otezla to appease antitrust regulators' concerns, the company said in a statement.

Bristol-Myers shares fell as much as 7% to $45.89 in New York, the biggest intraday drop since the deal was announced on Jan. 3. Celgene declined as much as 4.7% to $94.26.

Otezla is a major product for Celgene, bringing in $1.86 billion last year, and was seen as an important driver of future growth as the two companies knit together their businesses. Bristol-Myers has been battling Merck & Co. for dominance in the field of cancer immunotherapy, while Celgene's blockbuster Revlimid for blood cancers is expected to face lower-priced competitors in coming years.

Otezla has as much as a decade of strong sales ahead, according to analysts' estimates surveyed by Bloomberg. Now, a rival drugmaker will get the rights to the pill, potentially at a discounted price. Johnson & Johnson's Janssen unit has said it's interested in pursuing an oral psoriasis treatment through an acquisition or its own pipeline.

Bristol-Myers is researching another type of therapy for psoriasis known as a TYK2-inhibitor that would likely compete with Celgene's blockbuster drug. While the drugs work differently, the overlap raised concerns from regulators, according to the statement. By divesting Otezla, Bristol-Myers is electing to sell a blockbuster in favor of a promising, though still experimental, therapy.

"Divesting Otezla a surprise to us and removes one of the newco's growth drivers," Vamil Divan, an analyst with Credit Suisse Group AG, said in a note to clients.

Taking Longer

Bristol-Myers also said that the deal will take longer to close than it had expected. Its new target is the end of 2019 or early 2020, pushed back from a previous goal of Sept. 30. The FTC review is ongoing, the company said, and European regulators will review it as well.

"Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene," the company said in the statement. It plans to use the proceeds to pay off debt.

The increased oversight spooked investors in another biotechnology company facing regulatory review. Earlier this month, the FTC requested more information about Spark Therapeutics Inc.'s proposed sale to Roche Holding AG, sending the gene therapy company's shares falling. Spark's shares dropped as much as 3.6% to $101.25 on the news of the Otezla divestiture.

In a research note, Jefferies analyst Michael Yee said it remains to be seen what the news could mean for the industry.

"We continue to be mindful and are carefully watching to get a better handle on if we are in a more aggressive FTC era for biotech," he wrote in a note to clients.

Separately, Bristol-Myers said that its cancer drug Opdivo, its No. 2 product, had failed a clinical trial treating liver cancer patients. The medicine faces multiple competitors that use the same mechanism to help the immune system attack tumors, and Bristol-Myers' rivals have been attempting to get the drugs approved in as many different types of cancer as possible.

(Updates with details about Bristol-Myers's psoriasis treatment in fourth paragraph.)

To contact the reporters on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net;Riley Griffin in New York at rgriffin42@bloomberg.net

To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Mark Schoifet, Timothy Annett

For more articles like this, please visit us at bloomberg.com

©2019 Bloomberg L.P.

COMMENTS

More Related News

Trump Administration Moves to End Food Stamps for 700,000
Trump Administration Moves to End Food Stamps for 700,000

(Bloomberg) -- The Trump administration announced a plan Wednesday to end food-stamp benefits for about 700,000 Americans, issuing a new regulation that makes it harder for states to gain waivers from a requirement that beneficiaries work or participate in a vocational training program.Agriculture Secretary Sonny Perdue said the new rule will move more food-stamp recipients "toward self-sufficiency and into employment."Conservatives have long sought cuts in the federal food assistance program for the poor. House Republicans tried to impose similar restrictions last year when Congress renewed the program but were rebuffed in the Senate.The work requirement covers "able-bodied" recipients....

Stocks Rally on Fresh Hopes for U.S.-China Deal: Markets Wrap
Stocks Rally on Fresh Hopes for U.S.-China Deal: Markets Wrap

(Bloomberg) -- Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.Stocks extended gains in Europe and U.S. equity futures turned higher after a news report that China and America were moving closer to a trade deal. Treasuries erased earlier gains.Financial services

Support for Nationalist Sweden Democrats Jumps to Record in Poll
Support for Nationalist Sweden Democrats Jumps to Record in Poll

(Bloomberg) -- Backing for the nationalist Sweden Democrats surged in yet another poll, confirming that the party is now a contender to become the largest political force in the country.Some 22.6% of Swedes would vote for the Sweden Democrats if an election was held today, according to the bi-annual poll by the country's statistics agency. That's up from 17.1% in the poll in May. Prime Minister Stefan Lofven's Social Democratic Party, which has dominated Swedish politics during much of the 20th century, lost support but was still ahead of the nationalists at 26.3%.The result was the worst to date for the Social Democrats in a Statistics Sweden poll, while support for the Sweden Democrats...

U.S.
U.S. 'Likely' to Bring New Charges in Giuliani-Allies Case

(Bloomberg) -- The U.S is "likely" to bring additional charges in a case against Lev Parnas and Igor Fruman, associates of Rudy Giuliani who are accused of skirting campaign contribution limits as part of a plot to oust the American ambassador to Ukraine, a prosecutor said.The comment was made Monday at an hour-long court hearing in Manhattan. Speaking in response to a question from U.S. District Judge Paul Oetken about whether the government planned to file additional charges, Assistant U.S. Attorney Douglas Zolkind said: "Certainly the investigation is ongoing. We think a superseding indictment is likely, but no decision has been made. It's something we continue to evaluate."Parnas and...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Economy